Verve Therapeutics Partners with Novartis for Gene Editing Drug
| Field | Detail |
|---|---|
| Company | Verve Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Apr 14, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, gene-therapy, licensing, pre-clinical
Related Tickers: NVS
TL;DR
Verve inks $50M deal with Novartis for gene editing therapy VERVE-101. Big pharma backing!
AI Summary
Verve Therapeutics, Inc. announced on April 14, 2025, that it has entered into a clinical collaboration with Novartis Gene Therapies to advance VERVE-101, a gene editing medicine for the treatment of heterozygous familial hypercholesterolemia (HeFH). The collaboration will focus on the ongoing Phase 1b study of VERVE-101 and potentially future clinical development. Verve Therapeutics will receive an upfront payment of $50 million from Novartis Gene Therapies, with potential for additional milestone payments and royalties.
Why It Matters
This collaboration with a major pharmaceutical company like Novartis could significantly accelerate the development and potential commercialization of Verve's innovative gene editing therapy for a widespread genetic condition.
Risk Assessment
Risk Level: medium — While the partnership provides significant funding and validation, the success of VERVE-101 is still dependent on clinical trial results and regulatory approval.
Key Numbers
- $50 million — Upfront Payment (Received from Novartis Gene Therapies for collaboration on VERVE-101.)
Key Players & Entities
- Verve Therapeutics, Inc. (company) — Registrant
- Novartis Gene Therapies (company) — Collaborating Party
- VERVE-101 (drug) — Gene editing medicine
- $50 million (dollar_amount) — Upfront payment from Novartis
- April 14, 2025 (date) — Date of Report
- heterozygous familial hypercholesterolemia (HeFH) (medical_condition) — Target disease for VERVE-101
FAQ
What is the primary purpose of the clinical collaboration between Verve Therapeutics and Novartis Gene Therapies?
The collaboration is to advance VERVE-101, a gene editing medicine, through its ongoing Phase 1b study and potentially future clinical development for heterozygous familial hypercholesterolemia (HeFH).
What is the name of the gene editing medicine Verve Therapeutics is developing?
The gene editing medicine is named VERVE-101.
What is the financial arrangement for this collaboration?
Verve Therapeutics will receive an upfront payment of $50 million from Novartis Gene Therapies, with potential for additional milestone payments and royalties.
What condition is VERVE-101 intended to treat?
VERVE-101 is intended to treat heterozygous familial hypercholesterolemia (HeFH).
When was this report filed?
This Form 8-K report was filed on April 14, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Verve Therapeutics, Inc..